Sol-Gel Technologies (SLGL) Asset Utilization Ratio (2018 - 2026)
Sol-Gel Technologies (SLGL) reported Asset Utilization Ratio of 0.42 for Q1 2026, up 8.49% year-over-year from 0.38 in Q1 2025, and down 30.55% quarter-over-quarter from 0.6 in Q4 2025.
Sol-Gel Technologies (SLGL) Asset Utilization Ratio (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 9 years of Asset Utilization Ratio data on file, last reported at 0.42 in Q1 2026.
- Asset Utilization Ratio for Q1 2026 came in at 0.42, up 8.49% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.42 (up 8.49% YoY), and the FY2025 annual result was 0.59, up 107.31% from the prior year.
- Asset Utilization Ratio retreated to 0.42 in Q1 2026 per SLGL's latest filing, from 0.6 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 61.36 in Q4 2022 and troughed at 0.02 in Q3 2023.
- A 5-year average of 14.97 and a median of 0.42 in 2026 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2022 and 2023: Asset Utilization Ratio jumped 56136.96% in 2022, then slumped 99.96% in 2023.
- A 5-year view of Asset Utilization Ratio shows it stood at 61.36 in 2022, then tumbled by 99.95% to 0.03 in 2023, then jumped by 926.91% to 0.29 in 2024, then jumped by 105.67% to 0.6 in 2025, then sank by 30.55% to 0.42 in 2026.
- Business Quant data shows SLGL's Asset Utilization Ratio at 0.42 in Q1 2026, 0.6 in Q4 2025, and 0.51 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 0.42 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.42 |
| Dec 31, 2025 | 0.60 |
| Sep 30, 2025 | 0.51 |
| Jun 30, 2025 | 0.72 |
| Mar 31, 2025 | 0.38 |
| Dec 31, 2024 | 0.29 |
| Sep 30, 2024 | 0.27 |
| Jun 30, 2024 | 0.16 |
| Dec 31, 2023 | 0.03 |
| Sep 30, 2023 | 0.02 |
| Jun 30, 2023 | 0.09 |
| Dec 31, 2022 | 61.36 |
| Sep 30, 2022 | 56.92 |
| Jun 30, 2022 | 54.50 |
| Mar 31, 2022 | 48.27 |
| Dec 31, 2021 | 0.39 |
| Sep 30, 2021 | 0.10 |
| Jun 30, 2021 | 0.12 |
| Mar 31, 2021 | 0.11 |
| Dec 31, 2020 | 0.14 |